RxDoctor Payments DataLook up a doctor →

Adriana Walsh, PA

Physician Assistant · Athens, OHNPI 1245446418

Payments from drug & device makers

$14,512in general payments, 2019–2025

Across 638 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • AbbVie$2K
  • Novartis$991
  • Lilly USA, LLC$978
  • Journey Medical Corporation$879
  • Genentech USA, Inc.$764
  • plus $6K from 26 others

What the payments were for

  • Consulting fees$2,31316%
  • Travel & lodging$1351%
  • Food & beverage$11,12377%
  • Education$9426%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,512 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$291,269
Medicare patients
970
Services billed
11,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab118$440,591
Cosentyx Unoready PenSecukinumab43$362,611
Cosentyx Sensoready (2 Pens)Secukinumab28$268,170
Skyrizi PenRisankizumab-Rzaa12$245,694
TremfyaGuselkumab16$209,410
Humira(Cf) PenAdalimumab16$170,494
OtezlaApremilast17$77,637
Dupixent SyringeDupilumab18$65,756
Clobetasol Propionate114$4,536
Betamethasone Dipropionate100$3,478
Desonide43$2,768
Fluorouracil36$2,283
Doxycycline Monohydrate98$2,050
Clindamycin Phosphate46$1,985
Ketoconazole105$1,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$3,241$209,41016 claims
AmgenOtezla$463$77,63717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Athens

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →